Priority 2 from the Juvenile Idiopathic Arthritis (Netherlands) PSP

UNCERTAINTY: What is the best treatment plan for each individual patient? (e.g. start a biological directly, which one, what to do when the first one does not work, and how can medication best be tapered off?) (JLA PSP Priority 2)
Overall ranking 2
JLA question ID 0094/2
Explanatory note This question is about precision medicine, and asks what treatment is effective for which patient. Importantly, it also asks about tapering off medication when the disease is in remission.  

Systematic review - Davies et al. Efficacy of biologic therapy across individual juvenile idiopathic arthritis subtypes. A systematic review. Semin Arthritis Rheum 2017;46:584-593.

Systematic review-based + expert panel - Ringold et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis and enthesitis. Arthritis Rheumatol 2019;71:846.

Health Research Classification System category  Inflammatory and immune system
Extra information provided by this PSP
Original uncertainty examples See data spreadsheet on JLA website
Submitted by See data spreadsheet on JLA website
PSP information
PSP unique ID 0094
PSP name Juvenile Idiopathic Arthritis (Netherlands)
Total number of uncertainties identified by this PSP. 53  (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website)
Date of priority setting workshop 7 February 2020